New Perspectives for Prosthetic Valve Endocarditis: Impact of Molecular Imaging by FISHseq Diagnostics

Abstract Background The microbial etiology of prosthetic valve infective endocarditis (PVE) can be difficult to identify. Our aim was to investigate the benefit of molecular imaging technique fluorescence in situ hybridization (FISH) combined with 16S rRNA-gene polymerase chain reaction (PCR) and se...

Full description

Saved in:
Bibliographic Details
Published inClinical infectious diseases Vol. 76; no. 6; pp. 1050 - 1058
Main Authors Hajduczenia, Maria M, Klefisch, Frank R, Hopf, Alexander G M, Grubitzsch, Herko, Stegemann, Miriam S, Pfäfflin, Frieder, Puhlmann, Birgit, Ocken, Michele, Kretzler, Lucie, von Schöning, Dinah, Falk, Volkmar, Moter, Annette, Kikhney, Judith
Format Journal Article
LanguageEnglish
Published US Oxford University Press 21.03.2023
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Abstract Background The microbial etiology of prosthetic valve infective endocarditis (PVE) can be difficult to identify. Our aim was to investigate the benefit of molecular imaging technique fluorescence in situ hybridization (FISH) combined with 16S rRNA-gene polymerase chain reaction (PCR) and sequencing (FISHseq) for the analysis of infected prosthetic heart valves. Methods We retrospectively evaluated the diagnostic outcome of 113 prosthetic valves from 105 patients with suspected PVE, treated in 2003–2013 in the Department of Cardiac Surgery, Charité University Medicine Berlin. Each prosthetic valve underwent cultural diagnostics and was routinely examined by FISH combined with 16S rRNA gene PCR and sequencing. We compared classical microbiological culture outcomes (blood and valve cultures) with FISHseq results and evaluated the diagnostic impact of the molecular imaging technique. Results Conventional microbiological diagnostic alone turned out to be insufficient, as 67% of preoperative blood cultures were noninformative (negative, inconclusive, or not obtained) and 67% of valve cultures remained negative. FISHseq improved the conventional cultural diagnostic methods in PVE in 30% of the cases and increased diagnostic accuracy. Of the valve culture–negative PVE cases, FISHseq succeeded in identifying the causative pathogen in 35%. Conclusions FISHseq improves PVE diagnostics, complementing conventional cultural methods. In addition to species identification, FISH provides information about the severity of PVE and state of the pathogens (eg, stage of biofilm formation, activity, and localization on and within the prosthetic material). As a molecular imaging technique, FISHseq enables the unambiguous discrimination of skin flora as contaminant or infectious agent. Identification of the pathogen in prosthetic heart-valve endocarditis (PVE) is critical for diagnosis and therapy. Molecular diagnostics using FISHseq both directly visualizes and identifies the PVE pathogen. Thus, FISHseq delivered new diagnostic information in 30% of cases. Graphical Abstract
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Endocarditis Team, Charité–Universitätsmedizin Berlin.
Potential conflicts of interest. A. M. and J. K. are employees of and hold shares in MoKi Analytics GmbH in addition to being employed by Charité, and A. M. is founder and head of the private practice Moter Diagnostics. D. v. S. reports support for attending meetings from Insmed Germany GmbH (participation fee NTM Summit Berlin 8.10.2022). A. M. reports German Federal Ministry of Research and Education (BMBF) grants 13N15824 (FIELD), 13GW0414A (PROCEED), and 13N15815 (TEAM) (to A. M. and J. K.; MoKi Analytics) and European Union ITN grant 814168 (GROWTH) (to A. M.; MoKi Analytics); honoraria for lectures by BioMerieux and Chiesi; aupport for invited talks at meetings by BÄMI, ECCMID, SGM, ERASMUS+, and REMMDI; patents planned, issued, or pending for “Control Preparation for Fish Methods in Microbiology” (PCT/EP2016/051630); a leadership or fiduciary role with Konsiliarlabor Tropheryma whipplei, appointed by Robert Koch-Institute; shares with MoKi Analytics GmbH, and private practice with Moter Diagnostics. J. K. reports German Federal Ministry of Research and Education (BMBF) grants 13N15824 (FIELD), 13GW0414A (PROCEED), and 13N15815 (TEAM) (to J. K.; MoKi Analytics) and European Union ITN grant 814168 (GROWTH) (to J. K.; MoKi Analytics); support for attending meetings and/or travel from the German Society of Hygiene and Microbiology (DGHM) (2022); patent I 07/137 (2008) Crystalline EGFR-matuzumab complex and matuzumab mimetics obtained thereof; a role as Vice Speaker of the Young German Society of Hygiene and Microbiology; and financial or nonfinancial interests as Chief Executive Officer of MoKi Analytics GmbH, a start-up of Charité, since 2018. V. F. is affiliated with the German Heart Center–Berlin, Charite–University Hospital Berlin, DZHK, ETH-Zurich (Department of Health, Science, and Technology and Trasl. Cardiovascular Technology). He also declares institutional financial activities in relation to the following: educational grants (including travel support), fees for lectures and speeches, fees for professional consultation, and research and study funds with the following commercial entities: Medtronic GmbH, Biotronik SE & Co, Abiomed GmbH, Abbott GmbH & Co, KG, Boston Scientific, Edwards Lifesciences, Berlin Heart, Novartis Pharma GmbH, JOTEC/CryoLife GmbH, LivaNova, and Zurich Heart. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
ISSN:1058-4838
1537-6591
DOI:10.1093/cid/ciac860